Completed × Leukemia, Promyelocytic, Acute × Clear all
NCT01588015 2024-04-02

Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant

City of Hope Medical Center

Phase 1 Completed
36 enrolled
NCT00105001 2019-10-30

Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer

Fred Hutchinson Cancer Center

Phase 2 Completed
210 enrolled 15 charts
NCT00003396 2019-10-17

Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer

University of Maryland, Baltimore

Phase 2 Completed
42 enrolled
NCT00003398 2019-10-17

Bone Marrow Transplantation in Treating Patients With Hematologic Cancer

University of Maryland, Baltimore

Phase 4 Completed
45 enrolled
NCT00005092 2018-10-26

Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer

M.D. Anderson Cancer Center

Phase 1 Completed
7 enrolled
NCT01254578 2017-09-25

Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers

National Cancer Institute (NCI)

Phase 1 Completed
17 enrolled
NCT00217646 2015-04-28

Sorafenib in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndromes, or Blastic Phase Chronic Myelogenous Leukemia

National Cancer Institute (NCI)

Phase 1 Completed
36 enrolled
NCT00351975 2014-12-23

Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other Diseases

National Cancer Institute (NCI)

Phase 1 Completed
56 enrolled
NCT00301938 2013-09-30

7-Hydroxystaurosporine and Perifosine in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia or High Risk Myelodysplastic Syndromes

National Cancer Institute (NCI)

Phase 1 Completed
30 enrolled
NCT00006019 2013-06-24

Phenylbutyrate Plus Azacitidine in Treating Patients With Acute Myeloid Leukemia, Myelodysplasia, Non-Hodgkin's Lymphoma, Multiple Myeloma, Non-small Cell Lung Cancer, or Prostate Cancer

National Cancer Institute (NCI)

Phase 2 Completed